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A covalent linker allows for membrane targeting of an oxylipin
biosynthetic complex
Nathaniel C. Gilbert, Marc Niebuhr, Hiro Tsuruta, Tee Bordelon, Oswin Ridderbusch, Adam
Dassey, Alan R. Brash, Sue G. Bartlett, and Marcia E. Newcomer*
From the Department of Biological Sciences, Louisiana State University, Baton Rouge, LA 70803
Abstract
A naturally occurring bi-functional protein from Plexaura homomalla links sequential catalytic
activities in an oxylipin biosynthetic pathway. The C-terminal lipoxygenase (LOX) portion of the
molecule catalyzes the transformation of arachidonic acid (AA) to the corresponding 8R-
hydroperoxide, and the N-terminal allene oxide synthase (AOS) domain promotes the conversion of
the hydroperoxide intermediate to the product allene oxide (AO). Small angle X-ray scattering data
indicate that in the absence of a covalent linkage the two catalytic domains that transform AA to AO
associate to form a complex that recapitulates the structure of the bi-functional protein. The SAXS
data also support a model for LOX and AOS domain orientation in the fusion protein inferred from
a low resolution crystal structure. However, results of membrane binding experiments indicate that
covalent linkage of the domains is required for Ca2+-dependent membrane targeting of the sequential
activities, despite the non-covalent domain association. Furthermore, membrane targeting is
accompanied by a conformational change as monitored by specific proteolysis of the linker that joins
the AOS and LOX domains. Our data are consistent with a model in which Ca2+-dependent
membrane binding relieves the non-covalent interactions between the AOS and LOX domains and
suggests that the C2-like domain of LOX mediates both protein-protein and protein-membrane
interactions.
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The ability of the cell to respond to its environment is dependent upon effective coordination
of metabolic pathways. For those pathways that involve the biosynthesis of the arachidonic
acid (AA) - derived lipid mediators such as the leukotrienes, prostaglandins, and thromboxanes,
their coordination may be exceptionally challenging in terms of substrate acquisition and
specificity. The hydrophobic substrates partition into the membrane phase, and active sites that
recognize bulky hydrophobic compounds might be inherently promiscuous. Furthermore, the
highly reactive fatty acid hydroperoxide intermediates promote cellular oxidative damage if
their metabolism is not stringently regulated. Both compartmentalization of enzymes and
organization of multi-enzyme complexes are thought to provide cellular mechanisms for
“traffic control” in pathways for the synthesis of these potent signaling molecules (1-3). In
order to understand how coordination of biosynthetic pathways is achieved in the context of
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cell trafficking, and specifically how facilitated transfer of intermediates between active sites
might be a means to regulate pathway flux, we have focused our efforts on an eicosanoid
biosynthetic enzyme that contains both 8R-lipoxygenase (8R-LOX) and allene-oxide synthase
(AOS) activities in a naturally occurring fusion protein.
Lipoxygenases, which catalyze the regio- and stereo- specific dioxygenation of
polyunsaturated fatty acids (4-6), are composed of two domains: an amino terminal β-barrel
domain and a largely α-helical catalytic domain (7-12). The amino terminal domain of
lipoxygenase resembles a C2 domain, the calcium-dependent membrane-binding module
found in phospholipases and kinases (13,14), and is referred to as the C2-like domain. The
structure of the independently expressed 8R-LOX domain of the fusion protein revealed clearly
defined calcium binding sites in its C2-like domain, and fluorescence data indicated that
Ca2+-binding amino acids are required for membrane-binding. A double mutant in which
amino acids in two of the Ca2+-sites are mutated does not bind membranes, but has wild-type
activity in a membrane-free assay (11). In addition, a deletion mutant lacking a putative C2-
like domain membrane-insertion loop common to 8R- and 5-LOX (but absent in 15-LOX) has
wild type activity in a membrane-free assay, but is impaired with respect to membrane binding:
enzyme activity is not stimulated by Ca2+ when assayed in the presence of liposomes (15). In
the context of the naturally occurring fusion protein, the C2-like domain is flanked by the N-
terminal AOS domain and the C-terminal LOX catalytic domain. The structure of the
independently expressed AOS domain has also been reported (16). P. homomalla AOS
structurally resembles catalase, both in terms of the polypeptide fold and the constellation of
amino acids that constitute the heme environment.
Early studies of oxylipin biosynthesis in the soft coral Plexaura homomalla led to the
identification of an activity in the microsomal fraction (17) that was subsequently attributed
to the bi-functional 8R-LOX-AOS fusion protein (18). The product of the two activities is now
considered a likely precursor of marine prostanoid derivatives such as the clavulones (19-21).
The bi-functional coral enzyme, or “fusion protein”, catalyzes successive steps in an eicosanoid
biosynthetic pathway: the transformation of arachidonic acid to 8R-
hydroperoxyeicosatetraenoic acid (8R-HPETE) by the 8R-LOX domain and the subsequent
conversion of the intermediate to the corresponding allene oxide by the AOS domain. It has
been postulated that when two interacting proteins are fused, successive mutations will
eventually create an optimized protein-protein interface (22). Thus, it is predicted that fusion
proteins, when expressed independently should associate via these optimized protein-protein
interfaces. Furthermore, what occurs as a fusion protein in one species may be found as a
complex of multiple polypeptides in another (e.g. fatty acid synthase), and thus existence of a
fusion protein in an organism may be indicative of interacting proteins in other organisms
(22).
We investigated the function of the covalent linkage of the AOS and LOX activities and present
evidence that the independently expressed domains associate in the absence of the covalent
linker. Small angle X-ray scattering experiments reported herein demonstrate that a
chromatographically purified complex of AOS and 8R-LOX (heterodimer, HD) recapitulates
the solution structure of the full length fusion protein (FP). Furthermore, SAXS data are
consistent with one of two models for AOS and 8R-LOX domain association inferred from a
low resolution crystal structure of the fusion protein. However, membrane-binding
experiments indicate that covalent linkage of the individual enzymatic domains is required for
Ca2+-dependent membrane targeting of the sequential catalytic activities. Limited proteolysis
and membrane binding experiments with FP suggest that Ca2+-dependent membrane binding
is accompanied by a conformational change that releases AOS from non-covalent interactions
with the LOX domain. The construction of a mutant form of the naturally occurring fusion
protein in which a tobacco etch virus (TEV) protease cleavage site is positioned between the
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AOS and LOX domains allowed us to distinguish conformational states of FP that differ in
access to the TEV-protease site. Taken together, our observations suggest that the covalent
linker that links the LOX and AOS domains in FP is required to compartmentalize the
sequential catalytic activities at the membrane.
EXPERIMENTAL PROCEDURES
Construction of the native AOS-LOX fusion protein expression plasmid
Plasmids containing the genes for the AOS and lipoxygenase domains of FP were used as
templates to amplify the genes for each by Polymerase Chain Reactions (PCR). The native
AOS-LOX fusion protein was reconstructed by overlap extension PCR. First, the lipoxygenase
gene was PCR-amplified using a forward primer designed to anneal at the beginning of the
coding sequence and a reverse primer having a 5’ BamHI restriction site for subsequent cloning.
Next, the AOS gene was PCR-amplified using a forward primer containing a 5’ NdeI restriction
site and a reverse primer that anneals to the last 19 nucleotides of the AOS gene and has a 5’
extension containing 22 additional nucleotides that are complementary to the first 22
nucleotides of the LOX gene. Both amplicons from the above PCR reactions were then
combined and overlap PCR was done in which the 22 nucleotide overlap amplicons were
allowed to anneal and serve as the primers for DNA polymerase extension to create the gene
for the full-length AOS-LOX fusion protein. Included in the overlap PCR reaction was the
AOS forward primer and the LOX reverse primer so that amplification of the full-length AOS-
LOX gene would proceed. The full-length AOS-LOX DNA was gel-purified and cloned into
pSTBlue-1 (Novagen) at the EcoRV site. An NdeI/BamHI digestion excised the AOS-LOX
gene which was then ligated into pET28 (Novagen) digested with the same enzymes. The
resulting expression plasmid, pTBfusion, expresses the fusion protein under control of an
isopropyl-beta-D-thiogalactopyranoside (IPTG) inducible T7 promoter. Plasmid pTBfusion
was sequenced to confirm that no point mutations had occurred during PCR and to verify that
the junction between the AOS and LOX genes maintained the correct reading frame required
to yield the native FP.
Construction of AOS-TEVsite-LOX fusion protein expression plasmid
The AOS/TEVsite/LOX fusion was assembled in pLITMUS 28i (New England Biolabs) as
follows. The AOS sequence encoding amino acids 1-367 of FP was amplified by PCR using
a 5’ primer containing a KpnI site and a 3’ primer containing an AvrII site. The PCR product
was digested with AvrII and KpnI and cloned into pLITMUS 28i digested with the same
enzymes. The sequence encoding the 8R-LOX portion of FP (from amino acid 373 to the stop
codon) was amplified using a 5’ primer containing an AgeI site and a 3’ primer containing a
BamHI site. The PCR product was digested with AgeI and BamHI and cloned into AOS/
pLITMUS digested with the same enzymes.
The TEV cleavage site was constructed using synthetic oligonucleotides containing a SpeI
overhang at the 5’ end and an AgeI overhang at the 3’end. This linker was cloned into
AOS-8R-LOX/LITMUS digested with AvrII and AgeI. The resulting chimeric protein, AOS-
TEVsite-8R-LOX (TEV-FP), contains the sequence PSENLYFQGTG between amino acids
367 and 373 of the original fusion protein. The AOS-TEVsite-8R-LOX sequence was excised
from LITMUS 28i using NdeI and BamHI and cloned into pET28b digested with the same
enzymes. This construct was transformed into E. coli BL21 (DE3) cells for expression.
Protein expression and purification
The individually expressed LOX and AOS domains were purified as previously described
(11,16). FP was purified from an E. coli expression system. BL21 (DE3) cells carrying
pTBfusion were grown in Terrific Broth at 37 °C until the A600 exceeded 0.6, at which time
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the temperature was reduced to 18 °C. After 26 hrs at this temperature the cells were harvested,
pelleted by centrifugation, and frozen at -80 °C. Cell pellets were resuspended in Bugbuster
(Novagen) according to the manufacturer’s instructions, and the protease inhibitors pepstatin
and leupeptin were added. After the addition of DNase I (Sigma-Aldrich), the suspensions were
sonicated. Cell debris was removed by centrifugation and the supernatant was applied to Ni-
NTA agarose (GE Healthcare) in 10mM Tris (pH 8), 500mM NaCl (buffer A). The column
was washed with 10mM buffer A supplemented with 20mM imidazole, and subsequently
eluted with an imidazole gradient (20-200 mM in buffer A). The fractions containing FP had
absorbance maxima at 280 and 406nm. Further purification on mono-Q (20 mM Tris, pH 8,
0-500 mM NaCl) and Superdex-200 size exclusion chromatography (SEC) columns (GE
Healthcare) (10mM Tris, pH 8, 150mM NaCl) yields pure enzyme as judged by SDS-PAGE
and the ratio of A280 to A406. To ensure full heme substitution in the AOS domain, excess
heme was added prior to application of sample to the Superdex-200 column. TEV-FP was
expressed and purified according to the protocol for native FP.
Size-exclusion chromatograph
For preparative scale LOX+AOS heterodimer (HD) isolation, independently purified LOX and
AOS domains were mixed and applied to a Superdex-200 (GE Healthcare) column mounted
on an ÄKTA FPLC. Analytical runs to monitor complex formation were performed with a Bio-
Rad Biologics FPLC fitted with Pharmacia Superose-12 column buffered with 20-50 mM Tris
(pH 7.5), 150 mM NaCl at a flow rate of 1 ml/ min. In this system, the complex elutes at 12.5
mls and free AOS (as a dimer) elutes at 13.5 mls. Protein elution is simultaneously monitored
at 280 and 406nm with a Bio-Rad Quadtec detector. Absorbance at 406nm is due to the AOS
heme. HD has 1 heme for 1066 amino acids, and the absorbance at 280nm is greater than that
at 406nm. The reverse is true for AOS, which has 1 heme for 373 amino acids.
Small Angle X-ray Scattering Data
SAXS data were collected at SSRL beamline 4-2 (23) for both FP and HD purified by size
exclusion chromatography. HD and FP were concentrated to 10 mg/ml in Centricon-50
(Millipore) centrifugal filter devices. SAXS measurements were taken at concentrations
ranging from 1 to 10 mg/ml. The sample-to-detector distances of 1.0 and 2.5 m were used to
cover the Q range 0.01-0.3 Å-1, where Q is the momentum transfer 4πsin(θ)/λ with θ and λ
being the half scattering angle and the wavelength, respectively. The double crystal
monochromator was calibrated to give the X-ray beam energy of 9 keV. A MarCCD165
detector was used throughout the measurements, and detector pixel numbers were calibrated
to corresponding Q values by the (100) and related higher order reflections of silver behanate
powder sample placed at the sample position. All samples contained 20mM Tris (pH 8.0) and
150mM NaCl. A 30 μl sample aliquot was loaded into the quartz capillary cell maintained at
20 °C and continuously moved in the beam at 1μl/s by a computer controlled syringe pump
during the X-ray exposure to minimize radiation damage. A series of ten data frames with 15s
exposure each were recorded for the sample aliquots. Blu-ICE/DCS and MarParse programs
were used for data collection and processing, respectively (23). The radii of gyration and
forward scattered intensities I(Q=0) were calculated with Primus (24). The electron pair
distance distribution function was computed by running Gnom, an indirect Fourier transform
program (25). The SAXS experiments were repeated with the addition of 2mM CaCl2 for both
FP and HD. LOX and AOS scattering curves were calculated from their crystal structures
(monomeric LOX and dimeric AOS) with Crysol (26), which takes into account a hydration
layer. The calculated scattering intensities of LOX and dimeric AOS were arithmetically
summed at each Q value to simulate a scattering curve that would be expected for a simple
mixture without forming a complex. Crysol was also used to obtain scattering curves for the
two possible conformations of fusion protein inferred from a low-resolution crystal structure.
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The structures of the independently determined AOS and 8R-LOX structures docked according
to the 3.5 Å crystal structure were used for these calculations.
Crystal Structure Determination
FP crystals were obtained by the hanging-drop vapor-diffusion method with drops prepared
with 2:1:1 mixtures of FP (5 mgs/ml in 4mM CaCl2), detergent (1.8 mM Triton-X 100), and
precipitant (16% PEG 3350, 4% Tacsimate pH 6.0) at 22° C. Thin plate crystals in the
monoclinic space group C2 (a = 235.5, b = 77.5, c = 158.0 Å, β= 112.5°) diffract to 3.5 Å.
Diffraction data were collected at the protein crystallography beamline at the Center for
Advanced Microstructures and Devices at Louisiana State University on a MarCCD165
detector at 100° K. Indexing, integration, and scaling was done with HKL2000 (27). The
structure was solved by molecular replacement with MOLREP in the CCP4 suite (28) of
programs. Due to non-crystallographic symmetry (NCS), there are two molecules in the
asymmetric unit. A multicopy search with 2.0Å resolution models of both AOS (1U5U) and
an 8R-LOX deletion mutant ((15) and Neau et al., unpublished) positioned two monomers of
each in the asymmetric unit. After multiple cycles of manual rebuilding followed by translation,
libration and screw rotation (TLS) and NCS-restrained refinement in REFMAC5 (28), the
model included residues 3-367 of the AOS domain and residues 373-410, 418-447, 450-567,
599-677, 688-951, and 959-1066 of the LOX domain (Rwork/free 27.3/32.2). At this point,
electron density was visible in a 2|Fo-Fc| map contoured at 1σ that, with a single short break,
connects the C-terminus of an AOS module to the amino terminus of LOX. This density
accommodates the linker region that joins the AOS and LOX domains as required for the
SAXS-supported model. Data and refinement statistics are provided in Table I.
Liposome Preparation
Large unilamellar vesicles were prepared from a mixture of porcine brain phosphatidylcholine
(PC) and phosphatidyl-serine (PS) in 3:1 molar ratio (LUV), or with 1-stearoyl-2-Arachidonyl-
sn-Glycero-3 phosphatidyl choline (AA-PC) and porcine brain PS in a 3:1 molar ratio (AA-
LUV). All phospholipids were purchased from Avanti Polar Lipids. For LUVs that
incorporated fluorescent labels, either N-(1-pyrenesulfonyl)-1,2-dihexadecanoyl-sn-
glycero-3-phosphoethanolamine (pyS-DHPE; Molecular Probes) or N-(5-dimethylamino-
naphthalene-1-sulfonyl)-1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (dansyl-
DHPE; Molecular Probes) was included at 5%. The labeled LUVs are designated pLUV and
dLUV, respectively. Phospholipid pellets were suspended in buffer with eleven passes in a
mini-extruder assembly (Avanti Polar Lipids).
Membrane binding
Membrane binding was monitored by fluorescence resonance energy transfer (FRET) using
pyrene-labeled LUVs (pLUV). The spectral overlap between pyrene and heme was used to
monitor association of the AOS domain with the membrane. Protein was added to solutions of
pLUV (total phospholipid concentration 260 μM) in 50 mM Tris-HCl pH 7.5, 500 mM NaCl
in a sample volume of 175 μl. Three emission spectra were recorded for each sample in
triplicate: (1) protein only (2) after the addition of CaCl2 to a final concentration of 2mM, and
(3) after the addition of EDTA to a final concentration of 4 mM. The total dilution of the sample
after addition of CaCl2 and EDTA was 5%. Protein concentrations in the cuvette were as
follows: FP, 2μM; HD, 2μM 8R-LOX+3μM AOS; AOS, 3μM. All emission spectra were
recorded on a Jasco FP-6300 spectrofluorimeter with excitation and emission bandwidths set
to 2.5 and 5nm, respectively. The excitation wavelength was set at 280 nm. The spectra
(averages of triplicate samples) were not corrected for the 5% dilution.
Ca2+-dependent LOX membrane binding was also monitored in the presence of increasing
concentrations of AOS. 8R-LOX membrane binding was monitored by FRET using dansyl-
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labeled liposomes (dLUV) with the assay previously described (11). Briefly, the concentration
of 8R-LOX was held constant at 0.5 μM and that of AOS ranged from 0.16 to 1.3 μM. Emission
spectra (excitation wavelength 295 nm) were recorded for protein in 260μM dLUV, 50 mM
Tris (7.5), 500 mM NaCl, before and after the addition of 2mM CaCl2. Measurements were
performed in triplicate. Membrane binding was indicated by an increase in Dansyl florescence
(517 nm). AOS does not exhibit Trp fluorescence due to the presence of heme.
Protein binding to sucrose-loaded vesicles was monitored by ultracentrifugation in a method
similar to the one previously described (29). LUVs were prepared as described above, but in
the presence of 0.2M sucrose, and diluted 30-fold in 50 mM Tris (pH 7.5), 150 mM NaCl.
8R-LOX or FP were added to final concentrations of 80 nM. AOS was added at 320 nM. The
total phospholipid concentration was 80μM. In these assay conditions the molar ratio of protein
to liposomes was ~10:1. The mixture was aliquoted into eight 3ml volumes to which CaCl2
was added to final concentrations of 0, 16, 31, 63, 125, 250, 500, 1000μM. The samples were
centrifuged at 100,000 × g for 1 h. After ultracentrifugation, the supernatants were immediately
decanted and the pellets were dissolved in SDS loading buffer and applied to 10%
polyacrylamide gel. The intensities of Coomassie-stained bands were integrated with image
processing software (Adobe Photoshop, Adobe Systems Inc).
Susceptibly to cleavage by TEV-protease
Limited proteolysis experiments were performed to determine the impact of Ca2+-dependent
membrane binding on protease site accessibility. AOS-TEVsite-LOX fusion protein (20μg)
was incubated with TEV protease (Invitrogen) in 50 mM Tris pH 8, 0.5 mM EDTA, 1 mM
DTT, 260 μM LUV or AA-LUV, in the absence or presence of 2mM CaCl2. A similar
incubation was performed in the presence of the detergent dodecylmaltoside (260μM) rather
than LUV. Samples were maintained at 30 °C for four hours. The reaction was stopped by the
addition of 5X SDS-PAGE sample buffer and boiling. Reaction products were separated by
SDS-PAGE in 10% gels. While it has been reported that TEV protease is inhibited by some
detergents dodecylmaltoside does not affect the protease activity (30),. The concentrations of
phospholipids in the reaction mixtures correspond to those utilized in the FRET membrane
binding and standard 8R-LOX activity assays. The intensities of Coomassie-stained bands were
integrated with image processing software (Adobe Photoshop, Adobe Systems Inc).
Lipoxygenase activity of the 8R-domain
Activity of the 8R-LOX domain was measured using a stopped-flow spectrometer (Model
SX17MV, Applied Photophysics Ltd.)operating in the absorbance mode at 25° C (11,31). The
Ca2+-stimulated activity of wild-type 8R-LOX domain was monitored in the presence of
liposomes composed of either porcine-brain PC:PS (3:1) or AA-PC: PS (3:1) as previously
described (11).
RESULTS
AOS and LOX form a complex in the absence of covalent linkage
As mentioned above, and as described in the purification protocol for HD, independently
expressed AOS and LOX domains co-elute on a sizing column at a volume consistent with a
molecular weight of 122 kD: LOX and AOS form an αβ heterodimer (HD) in the absence of
a covalent linkage (Fig 1a). Addition of AOS in excess resulted in two clearly resolved peaks
on gel filtration, the earlier eluting AOS-LOX heterodimer and the free AOS at a retention time
compatible with its homodimer mass of 86 kD (Fig 1b). Formation of a complex between the
two proteins was disrupted by the D411A mutation in the C2-like domain of 8R-LOX (Fig.
1c). The peaks are smeared, suggesting that the interactions in D411A-LOX:AOS are
weakened and the complex is no longer stable under the gel filtration condition. A similar result
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was observed for the E419A mutation of 8R- LOX (data not shown). (D411 and E419
correspond to D39 and E47, respectively, of the LOX domain in the numbering convention of
Oldham et. al. (11).) D411 and E419 are Ca2+-binding residues located on the C2-like domain
proximal to the AOS-LOX covalent linker; and both the D411A and E419A mutants have wild
type activity in a membrane-free assay (11). This result, and the physical restrictions imposed
by the short linker between the two catalytic domains of the natural fusion protein, suggest that
the C2-like domain mediates non-covalent interactions between AOS and LOX. There are only
six amino acids between the last structured residue of the AOS domain and the first structured
residue of the LOX domain (11,16) and this short covalent linker is bound to situate AOS close
to the C2-like domain of 8R-LOX.
The complex recapitulates the structure of the fusion protein
SAXS experiments were performed to determine whether HD recapitulates the structure of the
native fusion protein. Measurements for both FP and HD were obtained at four concentrations
ranging from 1 to 10 mg/ml. The radii of gyration (Rg) values indicate the presence of mild
interparticle interference, but the electrostatic properties of the two different protein
preparations are indistinguishable (Fig 2a). There is no sign of concentration dependent
aggregation in the concentration range as indicated by nearly constant I(Q=0)/c values. The
~20% difference in forward scattering intensities of HD and FP is likely due to over/under-
estimation of the concentrations of the dilute samples prior to concentration by centrifugation.
As the Rg values for HD and FP are equivalent, dissociation of HD is not a likely explanation
for the difference.
The Rg value extrapolated to zero concentration was 37.5±0.3Å for both HD and FP. The
composite scattering curves for the two preparations, obtained by scaling and merging the
scattering curves at 1 and 10 mg/ml, measured at 2.5m and 1.0m sample-to-detector distance,
respectively, are highly similar (Fig. 2b). This result indicates that FP and HD have comparable
solution structures at the level of tertiary structure. The forward scattered intensities obtained
for FP and HD were consistent, within experimental error, with the expected molecular weights
as compared with lysozyme scattering intensities that were also recorded using the same
experimental setup. If LOX and AOS had been dissociated, a completely different scattering
curve would have been observed. The predicted curve for a mixture of LOX monomer and
AOS dimer (AOS is a dimer in solution and in the crystal structure) is also shown in Fig.2b.
The pair distance distribution functions for HD and FP are also essentially identical and give
a value of 115Å (~the largest dimension of the LOX domain) for the largest extent of the
molecule, further supporting equivalent solution conformations. The SAXS experiments
clearly support the supposition that the independently expressed AOS and LOX domains
associate to form a heterodimer that recapitulates the structure of the full length fusion protein.
As stable protein-protein interfaces require that complementary surfaces bury ~1000 Å2 surface
area (32-34), it is highly unlikely that the interface in HD differs from the natural interface in
the FP. If the covalent linker were to prevent an intra molecular association that is only possible
as an inter- molecular interaction, aggregation or oligomerization of the fusion protein would
occur at higher protein concentrations. Yet the fusion protein remains fully soluble at
concentrations as high as 26 mg/ml. We also investigated the effects of Ca2+ on the FP and
HD conformations. In the presence of 2 mM CaCl2, the radii of gyration extrapolated to zero
concentration were within 1 Å of the value observed for both HD and FP in the absence of
Ca2+ (data not shown). This difference in Rg indicates that Ca2+ binding does not promote a
substantial reorientation of the AOS and LOX domains of FP or impact HD formation.
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The crystal structure of the full length fusion protein
The 3.5 Å resolution structure of the fusion protein includes 365 of 372 residues of the AOS
domain and 637 of 694 amino acids of the 8R-LOX domain in the asymmetric unit (chains A
and C). The putative membrane insertion loops of the C2-like domain were among the parts
of the protein not visible in the electron density maps. In addition, despite the inclusion of
CaCl2 in the crystallization conditions, electron density cannot be unambiguously attributed
to Ca2+. The apparent lack of the cation could be due to the abundance of Ca2+ chelators in
the crystallization solution, but more likely reflects the limited resolution of the crystal
structure. The Ca2+ binding sites as defined by the structure of the LOX domain (11) are
accessible, and remnants of electron density are consistent with the binding sites and loops
modeled in that work. However, the absence of electron density for amino acids 568-598 is
somewhat surprising given that this region is visible in our 3.2Å LOX structure (11). However,
this part of the protein is devoid of packing contacts in the FP crystal lattice and is perhaps not
sufficiently restrained. In the initial cycles of refinement and map interpretation, there was no
electron density for the linker region that joins the AOS and LOX domains (367-372) for either
of the two molecules in the asymmetric unit. Moreover, the domains are oriented such that the
C-terminus of either AOS module is positioned sufficiently close (10.5 and 13.5 Å) to the
amino terminus of a LOX domain to be joined by the covalent linker. Thus the structure of FP
could not be determined with the crystallographic data alone. However, the SAXS data are
clearly consistent with only one of the two possible conformations of FP in the unit cell and
thus allowed us to distinguish which association of domains reflects an intra-molecular
interaction (Fig. 2b). After the Rwork/Rfree reached 27.3/32.2, electron density was visible for
a linker between the AOS and LOX domains of one of the monomers (chain C) in the
asymmetric unit (the termini separated by 13.5 Å). Furthermore, the linkage is exactly what
was predicted by the SAXS-supported model illustrated in Figure 3. Accordingly, the SAXS
data support our interpretation of this density as the linker and indicate that the orientation of
the catalytic domains in the crystal lattice reflects the solution structure of FP.
Note that in the FP structure (Fig. 3) helix α2 of AOS makes contacts with both the C2-like
and catalytic sub-domains of LOX. The intra-molecular interface buries ~1000 A2 surface area
of each component (35) and is dominated by polar and charged interactions. Approximately
40% of the LOX interface is provided by the C2-like domain, and this interaction does not
involve the membrane insertion loops or the Ca2+ binding amino acids (e.g. D419). Consistent
with our observation that the addition of Ca2+ does not induce a conformational change
detectable in SAXS experiments, AOS does not obstruct access to the Ca2+ -binding amino
acids.
The independently expressed AOS domain is a dimer with an interface formed by a parallel
interaction of helices α2 from each of the monomers(16). Therefore, its participation on the
AOS-8R-LOX interface is consistent with the fact that we have never observed dimerization
of FP, or association of free AOS with FP or HD, assemblies which would require that helix
α2 is free to make the contacts it does in the AOS dimer. In the FP structure, helix α2 is flanked
by the C-terminal helix of the AOS domain and the C-terminal helix of the LOX domain (Fig
3b.).
The fusion protein binds membrane in a Ca2+-dependent manner
It was previously reported that the independently expressed 8R-LOX domain binds membrane
in a Ca2+-dependent manner, and that the C2-like domain amino acids D411 and E419 are
required for membrane binding, but not enzymatic activity (11). In addition, a deletion mutant
that lacks a putative membrane insertion loop in the C2-like domain does not display Ca2+-
stimulated activity in a membrane-based assay, but has wild type activity in the absence of
membranes. Furthermore, in conditions in which the wild-type enzyme is found in the
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membrane fraction, the LOX deletion mutant is soluble (15). In an effort to determine how the
presence of AOS might impact the membrane binding function of the 8R-LOX C2-like domain,
we monitored Ca2+-dependent membrane targeting of FP, 8R-LOX, and HD by FRET and
ultracentrifugation assays.
FRET data suggest that despite the fact that AOS and LOX form a non-covalent complex, AOS
is not localized to the membrane unless covalently bound to 8R-LOX. AOS membrane binding
was monitored with LUVs prepared with the fluorophore pryene incorporated into the
phospholipid head group (pLUV). The overlap of the pyrene fluorescence and heme
absorbance spectra is such that FRET between the pyrene–heme donor-acceptor pair occurs
when they are proximal. Each spectrum presented in Fig. 4a represents the average of three
independent measurements. Upon the addition of CaCl2 to a final concentration of 2 mM to
FP in the presence of pLUV, a 16% loss of pyrene fluorescence at 381 nm was observed,
consistent with a membrane-proximal location for heme (Fig. 4a). This signal is 9σ, where σ
is the standard deviation of the triplicate measurements. Addition of EDTA in excess restored
the pyrene fluorescence to 95% of its original value, a value indicative of total recovery of
signal if the 5% dilution of sample that occurs with the addition of CaCl2 and EDTA is taken
into consideration. Equivalent experiments were performed with LOX in the presence of an
excess of AOS (1.5 equivalents) and with AOS alone. No differences above 1σ were observed
for the spectra in the three conditions for either HD or AOS alone, i.e. spectra obtained after
the addition of Ca2+ and EDTA were within the standard deviation of triplicate measurements
of the initial conditions. Thus, heme is not brought into proximity of the membrane by the
addition of Ca2+ when AOS is not covalently bound to LOX.
Since the AOS domain does not co-localize to the membrane with LOX unless it is covalently
linked as it is in the fusion protein, and the C2-like domain that mediates membrane binding
is positioned between the LOX catalytic domain and the AOS domain, we asked whether
membrane and AOS binding by LOX are mutually exclusive. We utilized the Trp to dansyl-
labeled-LUV FRET assay previously described (11) to determine whether AOS inhibits
Ca2+-dependent membrane binding by 8R-LOX. We observed that in the presence of increasing
amounts of AOS in the FRET assay, fluorescence at 517nm decreased, consistent with
inhibition of membrane binding of 8R-LOX by AOS (Fig. 4b). AOS is a heme protein, and
thus the intrinsic Trp fluorescence of AOS is fully quenched. An alternate interpretation of the
AOS titration data is simply that there is physical interaction of AOS with 8R-LOX, and this
proximity quenches the signal of the Trp residues of the LOX C2-like domain and as a
consequence resonance energy transfer to the dansyl-fluorophore. However, we are able to rule
out this interpretation with the pyrene-heme FRET data, and the ultracentrifugation data
described below, that clearly indicate that AOS is not localized to the membrane unless
covalently bound to 8R-LOX. Loss of F517 with increasing AOS, therefore, is likely indicative
of overlap or communication between the AOS and membrane binding sites of the 8R-LOX
C2-like domain. LOX binds either AOS or membranes, but not simultaneously.
Results of additional membrane binding assays support the interpretation that AOS does not
accompany LOX to the membrane in the absence of a covalent linkage, and that the presence
of AOS impacts LOX membrane affinity. In these experiments, membrane targeting of FP,
8R-LOX, and HD to sucrose-loaded LUVs was monitored by ultracentrifugation in the
presence of 0 to 1 mM Ca2+ followed by SDS-PAGE of the LUV-protein pellets and Coomassie
blue staining. Fig. 5a shows the total amount of FP, 8R-LOX, or HD protein used in each test
run. The next panel (Fig. 5b) shows the amount of these proteins recovered in the 100,000 ×
g pellet after incubation with LUVs at different Ca2+ concentrations. The top panel of bands
in Fig. 5b (LOX-only incubations) shows that in the absence of calcium, no LOX protein was
pelleted, while the lowest [Ca2+] tested (16 μM) induced translocation, and the amount of
protein in the membrane fraction increased with higher Ca2+ concentrations. The middle panel
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of Fig. 5b shows the Ca2+ dependence of translocation of the fusion protein. As commented
on below, the total amount of fusion protein (FP) translocated was less than for LOX alone.
The lower panel (HD) shows that calcium induced translocation of LOX takes place, but not
that of AOS, in the absence of a covalent linker.
The intensities of the protein bands in Fig. 5b were quantified by densitometric scanning and
the results are summarized in Fig. 5c. This analysis clearly shows that membrane binding by
LOX alone, as a fusion protein, or as a heterodimer, is calcium-dependent. Furthermore,
translocation of AOS to the membrane requires a covalent linker to LOX. An additional point
that emerges from this analysis is that the presence of AOS, whether covalently bound or not
(FP, HD), attenuates the Ca2+-dependent targeting of 8R-LOX. The most likely explanation
for this effect is that the C2-like domain of 8R-LOX is involved in the interactions with AOS
and with the membrane, and there is competition between these dual functions. Thus the
membrane targeting function of the C2-like domain is functional in the fusion protein, but the
presence of AOS significantly attenuates membrane affinity in the conditions of the assay.
Membrane binding induces a conformational change in the fusion protein
The C2-like domain of 8R-LOX mediates LOX-membrane interaction (11) or LOX-AOS
interaction (Fig 1), but not both simultaneously (Figs 4 and 5). These data are consistent with
either overlap of the membrane and AOS binding sites, or some means of communication
between distinct binding sites. While the crystal structure, combined with the SAXS data,
eliminates the site-overlap interpretation, the limited resolution of the X-ray crystallographic
data makes it impossible to infer a mechanism for communication between the membrane-
binding and AOS interaction sites. Nonetheless, the data described above combine to suggest
that membrane binding by FP induces a conformational change which releases AOS from its
non-covalent interaction with LOX and frees up the C2-like domain for interaction with the
bilayer. In an effort to detect such a conformational change, we engineered a mutant form of
FP that contains a site for TEV-protease cleavage between AOS and LOX. The engineered FP,
designated TEV-FP, has wild type enzymatic and membrane binding activities, and is
indistinguishable from the wild type protein in SAXS measurements (data not shown).
The engineered FP that harbors the TEV protease site has an additional six residues in the linker
region. Because the linker is still relatively short, access to the recognition site by TEV protease
is hindered by the AOS and LOX domains. An intra-molecular association of the AOS and
LOX domains would further restrict access to the cleavage site. The results of the TEV-protease
susceptibility assay (Fig. 6), performed in quintuplicate, suggest that access to the TEV
cleavage site of TEV-FP is enhanced in the presence of Ca2+ and membranes. The yields of
free LOX and AOS were reproducibly increased when 2mM CaCl2 was added to the liposome
TEV-FP incubation, conditions which promote membrane binding by FP. In addition, a
concomitant decrease in the amount of TEV-FP was observed. The integrated intensities of the
LOX and AOS bands are depicted in Fig 6b. Note that in the absence of calcium (lanes 1 and
2) or membranes (lane 5) the amount of cleavage of FP is low and similar amounts of LOX
and AOS are produced. (The sum of the intensities of the AOS and LOX bands in lanes 1, 2,
and 5 (unstimulated cleavage) vary by less than 10%, and the FP band intensities vary by 12%.)
If both membranes and calcium were present (lanes 3 and 4), the sums of the AOS and LOX
bands are ~2 and ~3 times greater than those in lanes 1, 2, or 5. TEV-protease assays performed
in the presence of CaCl2 (but absence of membranes) do not yield significant increases in the
amounts of free LOX and AOS (data not shown) produced. This observation is consistent with
the fact that we are unable to detect a Ca2+ -induced change in the Rg of the fusion protein by
SAXS.
No Ca2+ -dependent stimulation of proteolysis of FP was observed in the presence of 300μM
dodecylmaltoside (lane 5), hence increased susceptibility to proteolysis depends on the
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presence of both Ca2+ and membranes. In contrast, more AOS and LOX are generated from
FP in the presence of arachidonyl-phospholipids (compare lanes 3 and 4). More significantly,
the impact of AA-LUV on TEV-site accessibility parallels the increase in LOX activity
observed in the presence of arachidonyl-PC containing liposomes relative to that observed with
porcine brain-PC containing vesicles. The enzymatic activity of 8R-LOX was 3-fold higher
when AA-PC was substituted for porcine brain PC in 3:1 PC:PS liposomes (data not shown).
8R-LOX activity with PC-esterified AA is not measurable in these assay conditions.
Consequently, the increased LOX activity with AA-LUV is likely due to enhanced LUV
binding by 8R-LOX and indicative of interaction of 8R-LOX with liposomes.
DISCUSSION
Although AOS and 8R-LOX naturally occur as a fusion protein, we have demonstrated that
the two protein domains associate in absence of a covalent linker. Small angle X-ray scattering
data suggest that the solution structures of the reconstituted heterodimer and full length fusion
protein are indistinguishable. The SAXS data are also consistent with a model of FP inferred
from a low resolution X-ray diffraction data. Despite the non-covalent association of the LOX
and AOS domains, AOS shows Ca2+-dependent membrane binding only when it is covalently
linked to LOX. These results indicate that the LOX-membrane interaction is not compatible
with LOX-AOS domain interaction. Furthermore SEC data and membrane binding
experiments indicate that both interactions require intact Ca2+ sites in the C2-like domain. In
contrast, the LOX-AOS interface revealed by a SAXS-supported crystal structure of FP does
not include the Ca2+ binding amino acids or putative membrane insertion loops of the C2-like
domain. However, the proximity of these membrane-binding structural elements to the AOS
domain in FP is indeed consistent with a model in which membrane binding by the LOX C2-
like domain destabilizes the non-covalent AOS and LOX domain interactions, given that the
membrane insertion loops of the C2-like domains must penetrate the bulky membrane bilayer.
What is less easily reconciled with the model is the observation that the point mutation D411A
also disrupts this domain interaction, as D411 and the membrane loop that it stabilizes are
outside the AOS and LOX domain interaction surface. However, the absence of a negative
charge at this position in the C2-like domain could have structural consequences that affect the
AOS-LOX interface.
Membrane binding by LOX in vitro is attenuated when it is covalently linked to AOS, as higher
CaCl2 concentrations are required to target FP to the membrane than 8R-LOX alone (Fig. 5).
Additionally, when free AOS is included in the membrane binding assay of the free 8R-LOX
domain, higher Ca2+ concentrations are required for translocation of LOX to the membrane.
In vivo the lower affinity of FP for membranes may be mitigated by a higher membrane to
protein ratio or by the advantage of having the AOS and LOX activities proximal for transfer
of the reactive hydroperoxide intermediate. Alternatively, the attenuation might be relieved by
some yet unidentified protein partner or signal.
Membrane binding induces a conformational change in FP. Insertion of a highly specific
protease cleavage site into a structurally defined position that links two independently folded
globular domains allowed us to monitor the intramolecular association of the domains in FP
under a variety of conditions. Limited proteolysis is routinely used to reveal conformational
changes induced by ligand binding in both single domain (36,37) and multi-domain (38,39)
proteins, and limited proteolysis has also been used to remove the C2-like domain in Soybean
LOX-1 and generate a mini-lipoxygenase with only a catalytic domain (40,41). In this work,
the engineered TEV-FP allowed us to specifically probe access to the linker region that joins
AOS and LOX.
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The SAXS supported crystal structure of FP is depicted in Fig. 3. The carboxyl terminus of
AOS (red) is joined to the amino terminus of LOX by a linker region not visible in the original
electron density maps. The LOX domain is comprised of two sub-domains: the C2-like domain
that mediates Ca2+-dependent membrane binding(11,15) and the catalytic domain. Our data
indicate that the Ca2+-dependent membrane binding activity is functional in the naturally
occurring fusion protein, and that as a consequence, the covalent linker that joins the AOS and
LOX domains provides a means to co-localize the downstream enzyme activity at the
membrane, perhaps facilitating transfer of the reaction intermediate between sequential
catalytic activities. Significantly, incubation of FP with phospholipid vesicles that incorporate
AA-PC increased TEV-protease susceptibility relative to that observed with LUV prepared
with standard porcine brain phospholipids. This enhanced protease susceptibility correlates
with an increased enzyme activity of the LOX domain. When LOX was assayed in the presence
of liposomes, Ca2+-stimulated enzyme activity in the presence of 3:1 AA-PC:PS was three-
fold greater than that measured in the presence of 3:1 porcine brain PC:PS.
The calcium binding residues of the 8R-lipoxygenase domain and putative membrane insertion
residues are also present in human 5-LOX, the enzyme that initiates the leukotriene biosynthetic
pathway. Ca2+ targets 5-LOX to the nuclear membrane (42-44), which is rich in arachidonyl-
phospholipids. Furthermore, the C2-like domain of 5-LOX mediates Ca2+-dependent targeting
(14,45,46). While Ca2+-dependent membrane binding activity has been localized to the C2-
like domain for 5-and 8R-lipoxygenases, this is not the case for 15-LOX. The association of
15-LOX with the membrane requires surface exposed hydrophobic amino acids in both the
C2-like and catalytic domains (47). This observation is consistent with key sequence
differences among LOX isozymes. While Ca2+ binding amino acids and putative membrane
insertion loops are conserved in 5- and 8R-lipoxygenases, as well as the C2-like domain of the
α-toxin phospholipase (46,48), these features are absent in 15-LOX and other LOX isozymes.
Pande et al. demonstrated that membrane fluidity modulates membrane binding by 5-LOX. In
addition, membrane penetration by the enzyme (as determined by Trp insertion into the bilayer)
and enzyme activity is enhanced with phospholipid cis-desaturation (49,50). Our results
suggest that membrane desaturation impacts the ability of the 8R-lipoxygenase domain to
penetrate the bilayer, since liposomes that contain AA as an esterified fatty acid promote TEV-
protease cleavage of TEV-FP, consistent with a membrane-induced conformational change.
Arachidonic acid serves as a precursor to numerous biologically active compounds, including
the prostaglandins, leukotrienes and thromboxanes, collectively known as eicosanoids.
Biosynthesis of prostaglandins and thromboxanes proceeds via the cyclooxygenase pathway
in which prostaglandin H synthase (also known as cyclooxygenase, COX) converts arachidonic
acid in two enzymatic steps to prostaglandin H2 (51). The leukotrienes are derived from the
lipoxygenase (LOX) pathway, in which 5-LOX catalyzes the two-step conversion of AA to
leukotriene A4 (52). Eicosanoids are known as local hormones, since they exert their effects
on cells close to their sites of synthesis and are rapidly degraded. Like the products of these
biosynthetic pathways, the intermediates are both labile and of limited solubility. One way to
optimize acquisition of a hydrophobic or labile substrate is to associate enzymes of the
metabolic pathways either covalently or non-covalently. Mandel et al. (53) suggested that
discrete protein complexes determine the fates of leukotriene intermediates (e.g. the relative
amounts of leukotrienes C4 vs. B4 produced). Similarly, prostaglandin biosynthetic pathways
have branch points that must be navigated by the intermediates common to multiple
prostaglandin products that induce fundamentally different, and often opposing, biological
responses. In an effort to determine whether co-localization of enzymatic activities might
impact the relative amounts of prostacyclin (PGI2) and thromboxane A2 produced, a bi-
functional enzyme that contained both cyclooxygenase (required for the biosynthesis of both
products) and PGI2 synthase was engineered (54). Indeed, cells expressing this construct
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produced elevated levels of PGI2 (54). In addition, Farmaki et al. (55) have reported the co-
localization of lipoxygenase, allene oxide synthase, and allene oxide cyclase, sequential
catalytic activities in the biosynthesis of jasmonic acid in plants. These results suggest that the
segregation of enzymes can regulate metabolic flux through alternative branches of
biosynthetic pathways. Macromolecular assemblies are likely a common theme in lipid-
mediator biosynthesis in plants and animals, and the naturally occurring fusion of the allene
oxide synthase to a Ca2+-dependent LOX is an example of how the covalent linkage of
sequential activities confers Ca2+-dependent membrane binding on an otherwise soluble
partner protein.
In the coral AOS-LOX fusion protein, the AOS and LOX catalytic domains flank a Ca2+-
dependent membrane targeting module, and AOS binding is not compatible with membrane
binding by the C2-like domain. A similar competition between protein:membrane-lipid and
protein:protein interactions has been described for protein kinase Cα and RhoGTPases. In this
case the C2-domain of Protein Kinase Cα mediates membrane binding and RhoGTPase
interaction in an either/or fashion (56). As a consequence of the covalent fusion of AOS and
LOX, Ca2+-dependent membrane binding by the LOX C2-like domain results in membrane
localization of both enzymatic activities. An additional advantage of joining the AOS and LOX
activities in a single polypeptide is suggested in Fig. 3b. Note that helix α2 is flanked by the
C-terminal helices of both the AOS and LOX domains. The AOS C-terminal helix provides
the proximal Tyr heme ligand for the active site prosthetic group. In LOX, the C-terminal helix
is followed by a 17 amino acid loop that penetrates the helical bundle of the catalytic domain
so that the carboxylate of the C-terminal Ile fills the coordination sphere of the active site iron.
One might speculate that this arrangement, in which a single helix could impact the
conformations of active site ligands for both domains, allows for communication between the
two catalytic sites.
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Size exclusion chromatography of 8R-LOX and AOS. Protein elution was simultaneously
monitored at 280 (black) and 406nm (gray). Absorbance at 406nm is due to the AOS heme.
(a) HD (LOX:AOS) elutes as a complex at 750s. (b) AOS in excess (2AOS:1LOX) yields two
clearly resolved peaks: HD (750s) and AOS (820s). HD has 1 heme for 1066 amino acids, and
the absorbance at 280nm is greater than that at 406nm. The reverse is true for AOS, which has
1 heme for 373 amino acids. (c) A 2:1 mixture of AOS: LOX(D411A). The mutation in the
LOX C2-like domain impairs HD formation: Note in panel (c) the absence of distinct HD and
AOS peaks, an indication that a heterodimer of LOX(D411A)+AOS is not stable in the size
exclusion chromatography column.
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Small Angle X-ray Scattering of HD and FP. (a) Radii of gyration and the forward scattered
intensity divided by protein concentration recorded for FP and HD as a function of
concentration. (b) Composite X-ray scattering curves and corresponding electron pair distance
distribution function (inset). Those curves for FP are shown in red, and HD in blue. Also shown
in green is the scattering curve predicted for a mixture of LOX and AOS in 1:2 molar ratio
without forming heterodimer, based on corresponding crystallographic structures. The same
FP curve (scaled at 0.1x) is reproduced with experimental error bars in the lower part of the
figure along with the predicted X-ray scattering curve (black, scaled at 0.1x)) for one of the
two low-resolution crystal structures of FP.
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SAXS-supported crystal structure of FP. (a) A cartoon and surface rendering of FP. The AOS
domain is colored N→ C (blue → red). The C2-like and catalytic sub-domains of the LOX
portion are in brown and beige, respectively. The gray spheres mark the positions of the
Ca2+ atoms in the 3.2 Å resolution structure of the LOX domain alone (2FNQ). Neither the
Ca2+ ions or the putative membrane insertion loops that they stabilize (one of which includes
D411, position marked by red oval) are observed with confidence in the FP structure. (b) Detail
of the structural elements that make up the AOS-LOX interface. In this rendering, which is
identical in orientation as (a), the LOX domain is also colored N→ C (blue → red). Amino
terminal AOS helix α2 (blue) is flanked by C-terminal helices of both the AOS and LOX
domains (red). Amino acid ligands for the catalytic irons of both domains are directly (AOS)
or indirectly (LOX) connected to these helical segments.
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Membrane binding monitored by FRET. (a) Pyrene-heme FRET. Emission spectra for pyrene-
labeled liposomes and fusion protein (FP, left), heterodimer (HD, middle), and AOS (right).
Protein was added to solutions of LUV in which pyrene-labeled phospholipid was incorporated.
Emission spectra were recorded for triplicate samples in three states: protein only (solid black),
plus CaCl2 to a final concentration of 2mM (dashed line), and plus EDTA to a final
concentration of 4 mM (solid gray). For FP, the addition of CaCl2 quenches the observed
fluorescence, and the subsequent addition of EDTA restores the signal (the spectra are not
corrected for dilution.) In contrast, no difference is observed for either the HD or AOS samples
in the three states. Thus heme, the prosthetic group of AOS, is only localized to the membrane
by Ca2+ when covalently bound to LOX. (b) AOS titration of Ca2+-dependent membrane
binding by 8R-LOX. Emission spectra for 8R-LOX alone (0.5 μM, solid black) and in the
presence of increasing AOS (from 0.16 to 1.3 μM). Ca2+-dependent binding of 8R-LOX to
LUV can be measured by FRET when dansyl-labeled phospholipids are incorporated into the
vesicles (dLUV (11)). Titration of the sample with AOS results in a quench of the dansyl signal.
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Protein pelleting with sucrose-loaded LUV’s. (a) An amount equivalent to the total protein in
the incubation mixture applied to an SDS-PAGE gel. (b) Protein pelleted with sucrose-loaded
LUV as a function of Ca2+ concentration. Protein and sucrose-loaded LUV, at concentrations
of CaCl2 from 0-1mM, were centrifuged at 100,000 × g for 1 hr. Membrane fractions were
applied to a 10 % SDS-PAGE and the protein visualized by Coomassie staining. (c) A plot of
the intensity of the protein bands vs. CaCl2 concentration. Free AOS (dotted line) does not
translocate to the membrane in the presence of its partner protein LOX.
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Accessibility to the TEV-protease Cleavage Site. (a) Cartoon of the model for membrane
binding by the FP. The TEV protease site is positioned in the linker between the AOS and LOX
domains (indicated by *). Ca2+-dependent membrane binding releases AOS from the non-
covalent interactions and results in improved access the TEV-cleavage site by protease. (b)
TEV-FP was incubated with TEV protease in buffer plus LUV prepared from 3:1 PC:PS (LUV)
or 3:1 AA-PC:PS (ALUV) in the presence or absence of 2 mM CaCl2. A parallel incubation
was performed with Dodecylmaltoside (300 μM) in place of LUV. The reaction was stopped
after 4 hours and the products separated by SDS-PAGE and visualized with Coomassie stain.
(c) A plot of the integrated LOX and AOS band intensities for the gel in (b). Baseline levels
of LOX and AOS are observed in the presence of LUV but absence of Ca2+ (lanes 1 and 2) or
in the presence of Ca2+ and detergent (lane 5). The addition of Ca2+, which promotes membrane
binding of TEV-FP, results in an increase in the LOX and AOS produced. When the liposomes
contain AA-PL, the stimulation is enhanced. Thus the phospholipid content impacts TEV-
protease susceptibility only in the presence of Ca2+, conditions which promote membrane
binding by of FP.
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Table 1
X-ray Data Processing and Refinement Statistics
Data collection
Space group C2
Cell parameters 232.5, 77.5, 158.0 Å
β=112.5°
Wavelength (Å) 1.38
Resolution (Å) 40-3.51 (3.63-3.51)
unique reflections 32,749 (2833)













rmsd from ideal geometry
 bond length (Å) 0.010
 bond angle (°) 1.23
Values for highest-resolution shell are given in parentheses. Rmerge = Σhkl [(Σj|Ij - <I>|)/Σj |Ij| ]; Rwork = Σhkl ||Fo| - |Fc||/Σhkl |Fo|, where Fo and
Fc are the observed and calculated structure factors, respectively. Rfree is computed for 5% randomly selected reflections omitted from the refinement
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